The HER2-targeted therapy trastuzumab has improved survival for patients diagnosed with HER2-positive breast cancer, and several case reports have even described long-term survival in patients with HER2-positive metastatic breast cancer (MBC) [4-8]. Here, ERBB2 is linked to breast cancer.